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The epidermal growth factor receptor (EGFR), which participates in signalling pathways that are deregulated in cancer cells, is
frequently mutated in colorectal-cancer cells. Cetuximab is a monoclonal antibody that specifically blocks the EGFR. We evaluated
the efficacy of cetuximab in weekly combination with irinotecan in metastatic colorectal cancer patients refractory to previous
treatments based on oxaliplatin or irinotecan. We included 55 heavily pretreated patients (colon/rectum: 34/11, M/F: 16/29, median
age 63 years, range: 27–79) whose disease had progressed during or within an oxaliplatin-based first-line chemotherapy and a
irinotecan-based second-line regimen. Patients were followed for tumour response and were also evaluated for the time to tumour
progression, and safety of treatment. Cetuximab was given at an initial dose of 400mgm
 2, followed by weekly infusions of
250mgm
 2. Irinotecan was administered weekly at the dose of 90mgm
 2. All patients were assessable for treatment efficacy and
safety response rate was 25.4% (95% CI: 21.7–39.6%); 38.2% (95 CI: 18.6–39.8%) of patients showed a disease stability as the best
response. As a consequence, the overall tumour control rate was 63.6% (95% CI: 46.4–70.6%). The median time to progression was
4.7 months (95% CI: 2.5–7.1 months) and the median survival time was 9.8 months (95% CI: 3.9–10.1 months). The most common
G3-4 noncutaneous side toxicities were: diarrhoea (16.4%), fatigue (12.7%) and stomatitis (7.3%). 89.1% of patients developed skin
toxicity and 32.6% of cases was of grade 3–4. No allergic reactions were identified at any courses in any patients. Fever was
documented in 27.3% of patients and was most commonly recorded after the first administration. Cetuximab has clinically significant
activity even in heavily pretreated colorectal cancer patients progressed after both oxaliplatin and irinotecan-based chemotherapy
regimens.
British Journal of Cancer (2006) 94, 792–797. doi:10.1038/sj.bjc.6603018 www.bjcancer.com
Published online 28 February 2006
& 2006 Cancer Research UK
Keywords: cetuximab; irinotecan; advanced colorectal cancer; phase II trial
                                                         
Colorectal cancer is the third most common cancer in the US, with
approximately 145000 new cases expected in 2005 (American
Cancer Society, 2005). Estimated 5-year survival rates range from
90% for patients with stage I disease to o10% for patients with
metastatic colorectal cancer (American Cancer Society, 2005).
Chemotherapy reliably enhances quality of life and prolongs
both progression-free survival and overall survival (OS) for
patients with metastic colorectal cancer (Grothey and Schmoll,
2001).
5-FU represented the mainstay treatment for patients with
advanced CRC for a long period and no other drugs provided any
real improvement in survival for CRC patients. However, several
phase III trials investigating combination regimens with FU-LV
plus irinotecan or oxaliplatin as first-line therapy have achieved an
improvement of DFS and OS suggesting that combining these
agents is advantageous (de Gramont et al, 2000; Douillard et al,
2000; Giacchetti et al, 2000; Goldberg et al, 2004).
Mainly owing to the introduction of irinotecan and oxaliplatin,
in the past decade, the median duration of survival among patients
with advanced colorectal cancer has increased from 12 months to
about 18–21 months (Grothey et al, 2004). Moreover, the benefit
of second-line chemotherapy has been clearly demonstrated by a
randomised controlled trial in advanced colorectal cancer
(Cunningham and Glimelius, 1999).
Chemotherapies, however, are limited by their lack of specificity
and are often associated with frequent and potentially severe dose-
limiting toxicities. Therefore, there is an urgent need for more
effective, tailored and better-tolerated treatments that specifically
target the processes pivotal to tumorigenesis and metastasis.
Further advances in the understanding of molecular biology have
led to the development of target-specific agents. The FDA recently
approved two targeted agents: an antivascular endothelial growth
factor (anti-VEGF) monoclonal antibody, bevacizumab and a
human epidermal growth factor receptor (HER-1/EGFR) targeted
monoclonal antibody, cetuximab as first and second-line meta-
static colorectal cancer therapy, respectively (Venook, 2005).
Epidermal growth factor receptor (EGFR), a member of the ErbB
family of receptors, is relevant in colorectal cancer because
expression or upregulation of the EGFR gene occurs in 60–80%
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sof cases. The EGFR signalling pathway regulates cell differentia-
tion, proliferation, migration, angiogenesis, and apoptosis, all of
which become deregulated in cancer cells (Salomon et al, 1995).
Cetuximab is a chimeric IgG1 monoclonal antibody that binds to
EGFR with high specificity and with a higher affinity than either
epidermal growth factor thus blocking ligand-induced phosphory-
lation of EGFR. In addition, cetuximab enhances the effects of
irinotecan and radiotherapy in experimental systems (Prewett
et al, 2002).
A phase II study evaluated the activity and safety of weekly
cetuximab plus irinotecan in patients with irinotecan-refractory
CRC. The response rate was 17% in 121 patients, who had
progressive disease on irinotecan (Saltz et al, 2001). A more
recent phase II trial also assessed the safety and efficacy of
single-agent cetuximab in patients with chemotherapy-refractory
mCRC who express HER-1/EGFR (Cunningham et al, 2004). In
this paper by Saltz and co-workers, 57 patients with EGFR-positive
colorectal cancer that were refractory to both fluorouracil and
irinotecan, were evaluated. The response rates were the following:
8.8% of the patients had a partial response to cetuximab
monotherapy, and 36.8% had stable disease (Cunningham et al,
2004).
Cunningham and co-workers compared cetuximab alone vs
cetuximab plus irinotecan in patients with irinotecan-refractory
colorectal cancer in a phase III trial. The response rates were 10.8%
for cetuximab alone and 22.9% for cetuximab plus irinotecan (14).
Moreover, the 1-year survival rates in this group of heavily
pretreated patients (29% in the combination-therapy group and
32% in the cetuximab monotherapy group) were encouraging
(Saltz et al, 2004).
In the present phase II trial, we evaluated the efficacy and safety
of the combination of cetuximab and irinotecan in EGFR-
expressing colorectal cancer patients that progressed after
oxaliplatin and irinotecan-based chemotherapies.
MATERIALS AND METHODS
Patients
We considered patients eligible if they were more than 18 years of
age and had stage IV, histologically confirmed colorectal
adenocarcinoma. In addition, immunohistochemical evidence of
EGFr expression measured semiquantitatively (40 on a scale of
0, 1þ,2 þ,o r3 þ) in a single reference laboratory (University
Campus Bio-Medico, Rome). These measurements were performed
and graded using a commercially available kit (EGFRpharmDx;
Dako Corporation, Carpentino, CA, USA) according to the
manufacturer’s instructions. Patients were permitted to undergo
the screening process for tumour EGFr expression before meeting
other entry criteria and before study entry. For example, patients
were allowed to undergo EGFr screening before study registration,
while still receiving initial irinotecan therapy, before documenta-
tion of clinical progression. However, to be included in this study,
patients were required before study entry to have demonstrated
radiologic evidence of failure, as determined by the treating
physician, on irinotecan or an irinotecan-containing regimen.
Patients were not permitted to have received additional chemo-
therapy between the time of documented irinotecan failure and
entry onto this clinical trial.
Other criteria for eligibility were: a ECOG performance-status
score p2, adequate haematologic function (haemoglobin
X9gdeciliter
 1; neutrophil count X1500mm
 3; platelet count
X100000mm
 3), renal function (serum creatinine o1.5 times the
upper limit of normal range), and liver function (total bilirubin
o1.5 times the upper limit of normal range; aspartate amino-
transferase and alanine aminotransferase o5 times the upper limit
of normal values).
To be eligible, patients must also have previously received one
oxaliplatin-based chemotherapy regimen (Capecitabi-
neþOxaliplatin or FOLFOX IV regimen, as first line) and one
Irinotecan-based based-chemotherapy (FOLFIRI regimen, as
second-line chemotherapy) for at least 2 months. All patients
were included if progression of disease was documented during
receipt of these regimens or within three months thereafter.
XELOX regimen was administered as following: Oxaliplatin
70mgm
 2 as continuous infusion for 12h (0800–2000) on days 1,
8 plus chronomodulated capecitabine 1750mgm
 2day
 1 per os
(0800 25% of total dose; 1800 25% of total dose; 2300 50% of total
dose), on days 1–14 every 21 days (Santini et al, 2005).
FOLFOX IV consisted of LV (200mgm
 2day
 1) followed by a 5FU
bolus (400mgm
 2day
 1)a n d2 2 - hi n f u s i o n( 6 0 0m gm
 2day
 1)f o r
2 consecutive days every 2 weeks with oxaliplatin 85mgm
 2 as a 2-h
infusion on day 1 (de Gramont et al, 2000).
FOLFIRI consisted of CPT-11 180mgm
 2 as a 90-min infusion
day 1; LV 400mgm
 2 as a 2-h infusion during CPT-11, immediately
followed by 5-FU bolus 400mgm
 2 and 46-h continuous infusion of
2.4–3gm
 2 every 2 weeks (Andre et al, 1999).
Disease progression was documented by computed tomography
(CT) or magnetic resonance imaging (MRI). At least one
unidimensionally measurable lesion was required. EGFR expres-
sion in the primary tumour or in at least one metastatic lesion was
performed, All the patients signed a consent form.
Study design and treatment
This is a single centre phase II trial conducted from February
2004 – February 2005. Cetuximab was given at a loading dose of
400mgm
 2, followed by weekly infusions of 250mgm
 2. Irino-
tecan was administered weekly at the dose of 90mgm
 2.
A histamine-receptor antagonist and Atropine (0.25mg) were
given as premedication before every infusion. Moreover, dexa-
methasone was given at the dose of 20mg before the induction
course and at the dose of 8mg in the further courses. A standard
antiemetic drug was always given in the premedication and in
the following days according to the physician’s opinion. All the
patients were to be treated until disease progression or un-
acceptable toxic effects occurred. In the case of disease progres-
sion, further anticancer treatments were allowed.
Tumour response was evaluated every 8 weeks with the use of
consistent imaging techniques (CT or MRI). Assessment was
performed by the investigators, who used the Response Evaluation
Criteria in Solid Tumors (RECIST) (Therasse et al, 2000).
Toxic effects were assessed according to the National Cancer
Institute Common Toxicity Criteria, version 2 (National Cancer
Institute Common Toxicity Criteria, 1998).
Modifications of the dose of cetuximab were performed only in
cases of toxic effects to the skin, and modifications in the dose of
irinotecan were made in cases of haematologic or nonhaematologic
toxic effects.
No grant support from Merck was given to anyone of the
investigators and to the University Campus Bio-Medico.
Statistical plan and analysis
A two-staged Simon accrual design was adopted for this phase II
trial. The minimum target activity level was 20% and early
discontinuation of the study was planned in the case of no
response in the first 12 assessable patients. A planned sample size
of 55 evaluable patients was chosen to better estimate efficacy. The
primary end point was the rate of confirmed radiologic tumour
response, as assessed by a local committee, in the intention-to-
treat population. Secondary endpoints were the evaluation of time
to disease progression (TTP), overall survival (OS), safety profile
and median time to response. The median time of response
duration was calculated from the date of response registration to
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sthe date of disease progression or death. All analyses were
performed following an intention to treat analysis method. The
time to progression was calculated as the period from the date of
starting treatment to the first observation of disease progression or
to death from any cause within 60 days after the start of treatment
or the most recent tumour assessment. The overall survival time
was calculated as the period from the date of starting treatment
until death from any cause or until the date of the last follow-up,
at which point data were censored. TTP and OS were both
determined by Kaplan–Meier product-limit method (Kaplan and
Meier, 1958).
Stratified permutation tests were carried out to explore the
association between tumour response and rash and between
tumour response and EGFR expression. Moreover, the difference
in terms of TTP according to the presence and severity of acne-like
rash was evaluated by the log-rank test (Peto et al, 1977).
The cut-off point for survival data was July 2005; for safety data,
it was March 2005. SPSS software (version 11.05, SPSS, Chicago,
IL, USA) was used for statistical analysis. A P-value of o0.05 was
considered to indicate statistical significance.
RESULTS
Between March 2004 and January 2005, 55 consecutive patients
were enrolled in this single centre phase II trial; all of them had
EGFR-positive tumors. The main characteristics of our patients
population are summarised in Table 1. The median number of
courses administered was 19 (range, 5–49 cycles). No protocol
deviations were reported in any of our patients. All patients were
evaluated for the declared study end points (tumour response,
safety, TTP e OS).
Efficacy analysis
For the intention-to-treat analysis, 55 patients were evaluated for
efficacy. The best objective responses were achieved as follows: 0
(0%) complete responses (CR), 14 (25.4%; 95% CI: 21.7–39.6%)
partial responses (PR), 21 (38.2%; 95% CI: 29.4–44.3%) stable
disease (SD) and 19 (34.4%; 38.2%; 95% CI: 29.4–44.3%) disease
progressions. Therefore, the overall response rate was 25.4% (95%
CI: 21.7–39.6%), while the disease control rate (partial respon-
seþdisease stabilization) was 63.6% (95% CI: 46.4–70.6%). The
median duration of response was 4.9 months in the cohort of
responding patients (95% CI: 2.1–8.2 months). The median TTP
was 4.7 months (95% CI: 2.5–7.1 months), while the median OS
time was 9.8 months (95% CI: 3.9–10.1 months). The survival
curves are reported in Figure 1.
Adverse events
All the 55 patients were included in the safety analysis. Skin
reactions were observed in 49 patients (89.1%). In 70.9% (39 out of
55 patients) an acne-like rash, which is characteristic of cetuximab
toxicity, was recorded. The other 10 patients (18.2%) with skin
toxicity developed a mix of seborrheic dermatitis-like eruptions
and maculopapular rash mostly on the face, trunk, and less
frequently, on the limbs. In 16 patients (29.1%) skin toxicity was
grade 3; all these patients were situated in the acne-like rash group.
The median time of appearance of cetuximab-related skin toxicity
was three weeks after the start of treatment (range: 1–8 weeks).
The acneiform rash showed some degree of spontaneous partial
improvement in the rash during the first 1 to 2 months of therapy
and was subjectively noted in many of patients without modifica-
tion of the cetuximab dose. Paronychial cracking was observed in
33 patients (60.0%). These lesions occurred either on the fingers or
toes and usually evolved into chronic deep and painful lesions, in
particular along the lateral surface of toes. Such lesions generally
appeared later than the acne-like rash and were relatively
persistent throughout the duration of the patient’s treatment.
After cetuximab interruption these lesions spontaneously re-
gressed. No patients experienced allergic reactions leading to
cessation of therapy.
Owing to persistent skin side effects cetuximab dose was
reduced (25% dose reduction) in 10 patients (18.2%)
Leucopenia and neutropenia were the most common haemato-
logical toxicities with an incidence of 25.4 and 32.7%, respectively.
However, neutropenia of grade 3–4 was recorded only in three
patients (5.4%), but it did not cause any dose reductions or
treatment discontinuation. No patients required administration of
granulocyte colony stimulating factors to recover after neutropenic
event. No neutropenic fever was recorded in our trial.
The most common nonhaematological toxicity were diarrhoea
(grade 3–4 in 26.4% of patients), fatigue (grade 3–4 in 12.7% of
patients), and stomatitis (grade 3–4 in 7.3% of patients). Owing to
nonhaematological toxicities irinotecan dose was reduced (25%
dose reduction) in 14 patients (25.5%). As a result of the
persistence of diarrhoea in two patients irinotecan was discon-
tinued and those patients completed the treatment only with
cetuximab.
All the data about the safety profile are summarised in Table 2.
Table 1 Baseline characteristics of the patients
Patient’s characteristics # of patients (%)
Total number 55 (100%)
Male/female 21/34 (38.2%/61.8%)
Age (years)
Median 63
Range 27–79
Performance status
ECOG 0 26 (47.3%)
ECOG 1 18 (32.7%)
ECOG 2 11 (20.0%)
Primary tumour site
Colon 38 (69.1%)
Rectum 17 (30.9%)
No of metastatic sites
1 16 (29.1%)
2 26 (47.3%)
3+ 13 (23.6%)
Sites of metastases
Liver 33 (60.0%)
Lung 23 (41.8%)
Nodes 19 (34.5%)
Local 12 (21.8%)
Other 24 (43.6%)
Prior adjuvant therapy
None 14 (25.4%)
FU/LV 32 (58.2%)
First-line regimen
XELOX 38 (69.1%)
FOLFOX 17 (30.9%)
Second-line regimen
FOLFIRI 55 (100%)
EGFR expression
Score 1 16 (29.1%)
Score 2 20 (36.4%)
Score 3 19 (34.5%)
Cetuximabþirinotecan in colorectal cancer
B Vincenzi et al
794
British Journal of Cancer (2006) 94(6), 792–797 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sCorrelation of response and survival with rash
There was a correlation between the presence and severity of the
acne-like rash and tumour response. In particular, patients with
a grade 3 rah showed an higher response rate (62.5%) vs those
patients with a grade 0, 1 and 2 (10.25%); this difference is
statistically significant (P¼0.006). Moreover, comparing patients
who developed a grade 3 acne-like rash with those who did not
develop this toxicity or developed a grade 1 or 2, a statistical
significant correlation was recorded between the acne-like rash
and TTP (P¼0.007). Moreover, a border line statistical significant
difference in terms of overall OS between the two groups was
identified (P¼0.06).
These data are summarised in Table 3 and are shown in
Figure 2.
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Figure 1 Kaplan–Meier survival plots for TTP (A) and OS (B)i n
advanced colorectal cancer treated with cetuximab plus irinotecan as third-
line anticancer therapy.
Table 2 Adverse events related to treatment
# of patients with toxicity (%)
Side effects All grades Grade 3–4
Haematological
Anaemia 7 (12.7%) 2 (3.6%)
Leucopaenia 14 (25.4%) 0 (0%)
Neutropenia 18 (32.7%) 3 (5.4%)
Thrombocytopaenia 6 (10.9%) 0 (0%)
Nonhaematological
Diarrhoea 28 (50.9%) 9 (16.4%)
Fatigue 26 (47.3%) 7 (12.7%)
Mucositis 21 (38.2%) 4 (7.3%)
Nausea/vomiting 18 (32.7%) 3 (5.4%)
Hypotension 9 (16.4%) 2 (3.6%)
Fever 15 (27.3%) 0 (0%)
Hypersensivity reaction 0 (0%) 0 (0%)
Acne-like rash 39 (70.9%) 16 (29.1%)
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Figure 2 Kaplan–Meier survival plots for TTP in advanced colorectal
cancer treated with cetuximab plus irinotecan as third-line anticancer
therapy according to the presence and severity of acne-like rash.
Table 3 Influence of acne-like skin rash on tumour response and survival
Tumour response # of patients (%) P-value
Grade 0-1-2 6/39 (10.25%) 0.006
Grade 3 8/16 (62.5%)
TTP Median TTP (95% C.I.) in months P-value
Grade 0-1-2 4.00 (3.6–4.4) 0.007
Grade 3 6.00 (5.3–6.7)
OS Median OS (95% C.I.) in months P-value
Grade 0-1-2 9.1 (4.1–9.7) 0.06
Grade 3 10.3 (3.9–11.3)
TTP: time to progression; OS: overall survival; 95% C.I.: 95% confidence interval.
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We evaluated the correlation between the degree of EGFR
expression and the response rate in all the 55 patients included
in our analysis. Interestingly, we failed to identify a statistical
significant correlation between the degree of EGFR staining and
tumour responses. In particular, the distribution of tumour
responses were: four partial response in the 16 patients with score
1þ (25%), four responses in the 20 with score 2þ (20%) and
six responses in the 19 with score 3þ (31.6%) (P¼0.708).
Furthermore, no statistically significant differences in terms of
both TTP and OS were identified according to EGFR staining
(respectively, P¼0.891 and 0.316).
DISCUSSION
The epidermal growth factor receptor is a transmembrane
glycoprotein that is involved in signalling pathways affecting
cellular growth, differentiation, proliferation, and programmed cell
death (Baselga, 2002). The receptor is present on the surface of
normal epithelium and is overexpressed in certain tumors. Such
overexpression has been associated with a poorer prognosis in
colorectal cancer (Hemming et al, 1992; Mayer et al, 1993).
Inhibition of this target can be achieved by antibodies directed
against the extracellular domain of the receptor, by inhibitors of
the dimerisation of the receptor or by small molecules that prevent
phosphorylation of the receptor. Cetuximab is a monoclonal
antibody against the extracellular binding domain of the receptor
and recently became the first such inhibitor to be approved in the
United States for the treatment of metastatic colorectal cancer
(Andre et al, 1999).
Preclinical studies have shown not only that therapeutic synergy
exists between cetuximab and chemotherapeutic agents, but also
that such synergy can occur in tumour cells already resistant to
irinotecan, a finding suggesting that the inhibitor may overcome
cellular resistance to irinotecan (Baselga and Albanell, 2002).
We designed this trial to investigate the efficacy and safety of a
combination of cetuximab with a weekly schedule of irinotecan.
This is the first clinical experience of an association of cetuximab
with a weekly schedule of irinotecan. In the paper by Cunningham
et al (2004) patients received irinotecan at the same dose and
schedule as that given during their most recent prestudy therapy.
As a consequence of this trial design the included patients received
a wide combination of irinotecan schedules.
Moreover, in this paper, the subset analysis revealed that
cetuximab-based therapy was similarly effective in patients who
had previously received oxaliplatin in addition to irinotecan before
entering the study (Cunningham et al, 2004). On the basis of this
result, we planned to include only patients that progressed also
after an oxaliplatin-based regimen. As a result of all these reasons
this trial is the first experience investigating the association of
cetuximab plus weekly cetuximab as third-line therapy in
advanced colorectal cancer patients.
Our results showed a response rate of 25.4% and a disease
stabilization of 38.2%. Moreover, the median TTP was 4.7 months
and the median OS was 9.8 months. These results are in their
essence comparable with the previous data (Cunningham et al,
2004), confirming that a pretreatment with oxaliplatin does not
represent a negative predictive factor for response to cetuximab
plus irinotecan.
In the previous trials, the side effects of cetuximab are fairly
mild, with an acne-like rash and drying and fissuring of the skin
the most common; hypersensitivity infusion reactions are less
frequent (occurring in 3% of patients, with death in fewer than 1 in
1000) (Cunningham et al, 2004). Although some degree of
acneiform rash occurs in most patients, severe eruptions resulting
in significant pain, pruritus, or infectious sequelae are rare. Of
note, the development and severity of the rash have been
correlated with an increased likelihood of an objective response.
In this trial, the association between the cutaneous toxicity and
tumour response is statistically significant (P¼0.006), confirming
previously published data. However, for the first time, we
investigated the impact of skin toxicity on TTP. This analysis led
us to identify a statistically significant correlation of acne-like rash
with TTP (P¼0.007) and a border-line significant difference also
in terms of OS.
The mechanism underlying the correlation between skin toxicity
and tumour response is currently unclear, however, some research
groups hypothesized that the rash is a surrogate indicator
of an adequate degree of receptor saturation by cetuximab. If this
is the case, then targeting doses to achieve a desired level of
cutaneous toxicity may further increase the efficacy of this agent.
While this is an appealing prospect from a potential efficacy point
of view, it would suggest, if true, that there might be a narrow
therapeutic window to work with for this agent (Perez-Soler and
Saltz, 2005).
The trials reported to date have included only patients with
immunohistochemical evidence of epidermal growth factor
receptor expression. However, the degree of such expression
appears to be unrelated to the likelihood of disease regression,
raising questions as to whether receptor overexpression should be
a prerequisite for cetuximab treatment and whether the drug
interacts with additional molecular targets (Cunningham et al,
2004). More recently, Chung et al, (2005) reported that colorectal
cancer patients with EGFR-negative tumors have the potential to
respond to cetuximab-based therapies. Furthermore, in our
experience the degree of EGFR expression did not represent a
predictive factor for response and survival. As a consequence of all
these observations, EGFR analysis by current immunohisto-
chemical techniques does not seem to have predictive value (Dei
Tos and Ellis, 2005).
In conclusion, this clinical trial provides the demonstration of a
substantial clinical activity of the association of cetuximab plus
weekly irinotecan as third-line treatment in oxaliplatin- and
irinotecan-pretreated colorectal cancer patients. In particular, a
previous treatment with an oxaliplatin based regimen does not
seem to represent a negative predictive factor for response.
Moreover, our data confirm that acne-like rash represents the only
consistent predictive factor for response and identify, for the first
time, a statistically significant impact of skin toxicity also in terms
of TTP. Phase III trials should be designed to compare the
association of cetuximab plus irinotecan vs best supportive care
after oxaliplatin and irinotecan failure in advanced colorectal
cancer patients.
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